Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
Taiho Oncology, Inc.
Taiho Oncology, Inc.
Adela, Inc
OncoNano Medicine, Inc.
Massive Bio, Inc.
Nurix Therapeutics, Inc.
Arcus Biosciences, Inc.
Tempus AI
Seagen Inc.
RAPT Therapeutics, Inc.
Taproot Health
Sanguine Biosciences
Corvus Pharmaceuticals, Inc.
Fate Therapeutics
Fate Therapeutics
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Incyte Corporation
MultiVir, Inc.
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals
INSYS Therapeutics Inc